Boston, MA, September 15, 2026 – Lumina Pharmaceuticals, a clinical-stage radiopharmaceutical company advancing fibrin-targeting theranostic agents, today announced that Cara Ferreira, Ph.D., Chief Executive Officer, will participate in Discovery on Target 2026, taking place September 28 – October 1, 2026 at the Sheraton Boston in Boston, Massachusetts. Discovery on Target highlights transformative scientific and technological advancements including innovation in small molecule target discovery and recent developments in antibodies, conjugates, and radioligand therapies.
Details
Event: Panel Discussion on “Defining Next-Generation Radioligand Therapies: From Molecular Design to Clinical and Commercial Success” with Cara Ferreira, PhD, CEO as panelist
Date and time: Tuesday, September 29, 2026, 11:05 am
Event: Presentation on “Development of a Novel Radioligand Therapy Targeting the Extracellular Matrix of Solid Tumors” with Cara Ferreira, PhD, CEO, as speaker
Date and time: Wednesday, September 30, 2026, 9:05 a.m.
Both events will take place at the Sheraton Boston, 39 Dalton Street, Boston, MA 02199.
About Lumina Pharmaceuticals
Lumina Pharmaceuticals is a clinical-stage radiopharmaceutical company distinguished by its innovative technology that targets novel biomarkers that are abundantly present in solid cancers yet largely absent in healthy humans. Lumina’s lead asset is a novel radioligand therapy (RLT) theranostic, targeting a hallmark of the tumor microenvironment of solid tumors. Led by industry-leading scientists and experienced executives, Lumina is committed to improving human health through its diagnostic and therapeutic radiopharmaceutical pipeline.
For further questions contact info@luminapharma.com.